Curasight A/S announces outcome of warrant exercise

Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces the outcome of the exercise of warrants of series TO2, which were issued in connection with Curasight A/S rights issue and directed issue of units earlier in 2024 (“TO2”). In total, 466,453 warrants of series TO2 were exercised, corresponding to a subscription rate of approximately 12.7 percent. Curasight is thus provided approximately DKK 5.4 million before deduction of transaction related costs.

Outcome of the exercise of warrants of series TO2

During the exercise period, 21 November - 5 December 2024, holders of TO2 had the right to subscribe for one (1) new share in Curasight at a subscription price of DKK 11.50 per share. In total, 466,453 warrants of series TO2 were exercised, corresponding to a subscription rate of approximately 12.7 percent. Curasight will thus receive approximately DKK 5.4 million before deduction of transaction related costs.

Conversion from interim shares to ordinary shares is expected to take place around 18 December 2024.

Number of shares and share capital

The exercise of TO2 means that the number of shares in the Company increases by 466,453 shares and the share capital increases by DKK 23,322.65, resulting in a dilution effect of approximately 2.2 percent. When the new shares from TO2 have been registered with the Danish Business Authority, the total number of shares in Curasight will amount to 21,148,880 and the share capital will amount to DKK 1,057,444.00.

Advisors

Sedermera Corporate Finance AB is the Company's financial advisor in connection with the capitalization. DLA Piper is the Company's legal advisor and Danske Bank is the settlement agent.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

For more information regarding the warrants, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.